Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Pharmaceuticals India Pvt. Ltd.

Division of Eisai Co. Ltd.
www.eisai.co.jp

Latest From Eisai Pharmaceuticals India Pvt. Ltd.

Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes

Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.

India Commercial

Eisai Primes Push For Biogen MS Range In India

Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.

Commercial Strategy

Indian Panel Nudges Eisai Towards Phase IV Compliance For Halaven

Eisai’s request to forego Phase IV studies for its anticancer, Halaven, has been turned down by an Indian expert panel, which has reminded the Japanese company of the conditional marketing authorization previously granted for the product. Eisai, for its part, now says it will follow the “necessary requirements” set out by the Indian regulator.

Post Market Regulation & Studies Review Pathway

Eisai Fortifies Play With India-Specific Priced Fycompa

Eisai expects products like Fycompa and Lenvima, backed by innovative price planks pivoted around improving patient access, to intensify growth in India. Fycompa now debuts at a sub-$1 per day pricing in India.

Commercial Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Eisai Co. Ltd.
  • Senior Management
  • Contact Info
  • Eisai Pharmaceuticals India Pvt. Ltd.
    Phone: (91) 22 2857 9740
    Krishanlal Marwah Marg
    Marwah Centre
    Mumbai, 400 072
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register